Prostate cancer markers
AssigneeIncyte Corporation
InventorsMary Faris, Christopher M. Turner
Life of this patent
Estimating the term…
Abstract
The present invention relates to a composition comprising a plurality of cDNAs which are differentially expressed in prostate cancer and which may be used in their entirety or in part as to diagnose, to stage to treat or to monitor the treatment of a subject with prostate cancer.
Claims18
A composition comprising a plurality of cDNAs that are differentially expressed in prostate cancer and selected from SEQ ID NOs:1-3, 5, 6, 8, 10-15, 17-19, 21, 23-28, 30, 32, 34-36, 38, 40, 42-45, 47-50, 52, 53, 55, 56, 58-65, 67, 68, 70-73, 75, 76, 78-86, 88-90, 92-97, 99-101 or their complements.
An isolated cDNA encoding a protein comprising the amino acid sequence of SEQ ID NO:36.
Dependencies are inferred from the claim text.